Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2016

01.03.2016 | Original Article

Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome

verfasst von: Sachin Punatar, Alok Gupta, Jayant Gawande, Bhausaheb Bagal, Libin Mathew, Sadhana Kannan, Navin Khattry

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Chronic graft versus host disease (cGVHD) is a common late complication of allogenic hematopoietic stem cell transplant (HSCT). We analyzed risk factors, pattern and long term transplant outcomes of cGVHD at a tertiary cancer centre. Seventy-seven consecutive patients who underwent HSCT for acute leukemia were included. Forty (52 %) patients developed cGVHD; 24 (60 %) extensive stage while 16 (40 %) limited stage. Oral cavity was the commonest site of involvement (25 patients) followed by liver, skin and lung. We found that female donor to male recipient transplant and diagnosis of acute lymphoblastic leukemia (ALL) were the only factors associated with increased risk of cGVHD. The incidence of leukemia relapse was 18 % in patients who developed cGVHD compared to 51 % in those who did not (P = 0.002). Four year overall survival and relapse free survival (RFS) were 62 and 46 % in patients who developed cGVHD compared to 29 % (P < 0.001) and 29 % (P < 0.001) in patients who did not develop cGVHD, respectively. We conclude that cGVHD is more common in male patients with female donors and in patients transplanted for ALL. Oral cavity is the commonest site of cGVHD in our patients and transplant related survival outcomes are superior in patients who develop cGVHD.
Literatur
1.
Zurück zum Zitat Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP (2008) Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transpl 28:121–129CrossRef Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP (2008) Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transpl 28:121–129CrossRef
2.
Zurück zum Zitat Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al (2002) Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 100:1192–1200CrossRefPubMed Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al (2002) Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 100:1192–1200CrossRefPubMed
3.
Zurück zum Zitat Lee SJ, Vogelsang G, Flowers ME (2003) Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl 9:215–233CrossRef Lee SJ, Vogelsang G, Flowers ME (2003) Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl 9:215–233CrossRef
4.
Zurück zum Zitat Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al (1990) Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459–2464PubMed Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al (1990) Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459–2464PubMed
5.
Zurück zum Zitat Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al (2003) Graft-versus-host disease following allogenic transplantation from HLA-identical sibling with anti thymocyte globulin-based reduced-intensity preparative regimen. Blood 102:470–476CrossRefPubMed Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al (2003) Graft-versus-host disease following allogenic transplantation from HLA-identical sibling with anti thymocyte globulin-based reduced-intensity preparative regimen. Blood 102:470–476CrossRefPubMed
6.
Zurück zum Zitat Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M (2013) Incidence and pattern of graft-versus-host disease in patients undergoing allogenic transplantation after non myeloablative conditioning with total lymphoid irradiation and anti thymocyte globulin. Bone Marrow Res. doi:10.1155/2013/414959 PubMedCentralPubMed Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M (2013) Incidence and pattern of graft-versus-host disease in patients undergoing allogenic transplantation after non myeloablative conditioning with total lymphoid irradiation and anti thymocyte globulin. Bone Marrow Res. doi:10.​1155/​2013/​414959 PubMedCentralPubMed
7.
Zurück zum Zitat Gota V, Pathak K, Mittal S et al (2014) A limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil for prophylaxis of acute graft versus host disease in allogeneic stem cell transplantation. Bone Marrow Transpl 49:S295 Gota V, Pathak K, Mittal S et al (2014) A limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil for prophylaxis of acute graft versus host disease in allogeneic stem cell transplantation. Bone Marrow Transpl 49:S295
8.
Zurück zum Zitat Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) Chronic graft versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217CrossRefPubMed Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) Chronic graft versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217CrossRefPubMed
9.
Zurück zum Zitat Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl 11:945–956CrossRef Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl 11:945–956CrossRef
10.
Zurück zum Zitat Higman MA, Vogelsang GB (2004) Chronic graft versus host disease. Br J Haematol 125:435–454CrossRefPubMed Higman MA, Vogelsang GB (2004) Chronic graft versus host disease. Br J Haematol 125:435–454CrossRefPubMed
11.
Zurück zum Zitat Dhédin N, Prébet T, De Latour RP, Katsahian S, Kuentz M, Piard N et al (2012) Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Bone Marrow Transpl 47:1564–1568CrossRef Dhédin N, Prébet T, De Latour RP, Katsahian S, Kuentz M, Piard N et al (2012) Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Bone Marrow Transpl 47:1564–1568CrossRef
12.
Zurück zum Zitat Konopacki J, Porcher R, Robin M, Bieri S, Cayuela JM, Larghero J et al (2012) Long-term follow up after allogenic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin. Haematologica 97:710–716PubMedCentralCrossRefPubMed Konopacki J, Porcher R, Robin M, Bieri S, Cayuela JM, Larghero J et al (2012) Long-term follow up after allogenic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin. Haematologica 97:710–716PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Solano C, Martinez C, Brunet S, Tomás JF, Urbano-Ispizua A, Zuazu J et al (1998) Chronic graft versus host disease after allogenic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case–control study. Bone Marrow Transpl 22:1129–1135CrossRef Solano C, Martinez C, Brunet S, Tomás JF, Urbano-Ispizua A, Zuazu J et al (1998) Chronic graft versus host disease after allogenic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case–control study. Bone Marrow Transpl 22:1129–1135CrossRef
14.
Zurück zum Zitat Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al (2002) Severity of chronic graft-versus-host disease: association with treatment related mortality and relapse. Blood 100:406414 Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al (2002) Severity of chronic graft-versus-host disease: association with treatment related mortality and relapse. Blood 100:406414
15.
Zurück zum Zitat Pidala J (2011) Graft-vs-host disease following allogenic hematopoietic cell transplantation. Cancer Control 18:268–276PubMed Pidala J (2011) Graft-vs-host disease following allogenic hematopoietic cell transplantation. Cancer Control 18:268–276PubMed
Metadaten
Titel
Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome
verfasst von
Sachin Punatar
Alok Gupta
Jayant Gawande
Bhausaheb Bagal
Libin Mathew
Sadhana Kannan
Navin Khattry
Publikationsdatum
01.03.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0506-5

Weitere Artikel der Ausgabe 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.